LONDON: OptiBiotix Health Plc, a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, is to commercially launch its innovative weight management solution SlimBiome Medical to the European market on May 7, at Vitafoods Europe 2019.[the_ad id=”31605″]SlimBiome, which is a CE marked medical device, offers a healthy, hunger-free weight management solution designed for use by itself, or as part of a calorie-restricted diet, to reduce hunger and help users achieve sustainable weight loss. Independent clinical studies show SlimBiome reduces hunger, cravings for sweet and savoury foods, and fat intake.
Taking place from May 7 until May 9, Vitafoods Europe 2019 brings together nutraceutical expertise from more than 110 countries. This year’s event will be held in Geneva, Switzerland and OptiBiotix will be exhibiting alongside Nutrilinea on stand B20.
This commercial launch follows on from the announcement that SlimBiome was granted medical device status and a CE mark in November 2018, followed by the appointment of Nutrilinea S.R.L as a manufacturer and the signature of distribution agreements for Greece, Cyprus and Bulgaria as well as the successful commercial launch to the UK market on April 29 2019.
Fred Narbel, Managing Director of the Prebiotics division, commented: “We are delighted to present SlimBiome Medical to the EU market at Vitafoods as it is one of the most significant annual nutraceutical events in Europe. The launch allows us to continue to deliver on our sales strategy of building multiple revenue streams across various sales channels because it will help us accelerate the expansion our distribution and sales network in Europe and beyond and support recent distribution agreements we have established.”